Investigator

Yixin Liu

Harbin Medical University

YLYixin Liu
Papers(3)
Graph-based deep lear…Computational identif…Cytomorphology and im…
Collaborators(2)
Yuming ZhaoGuohua Wang
Institutions(2)
Harbin Medical Univer…Northeast Forestry Un…

Papers

Graph-based deep learning for integrating single-cell and bulk transcriptomic data to identify clinical cancer subtypes

Abstract The integration of single-cell RNA sequencing (scRNA-seq) and bulk transcriptomic data has become essential for deciphering the complex heterogeneity of cancer and identifying clinical cancer subtypes. However, the inherent challenges posed by the high dimensionality, sparsity, and noise characteristics of scRNA-seq data have significantly hindered its widespread clinical translation. To address these limitations, we introduce single-cell and bulk transcriptomic graph deep learning, a graph-based deep learning method that synergistically integrates scRNA-seq and bulk transcriptomic data to precisely identify cancer subtypes and predict clinical outcomes. scBGDL constructs sample-specific gene graphs modeling complex gene–gene interactions and cellular relationships. The architecture employs Graph Attention Networks for feature aggregation, MinCutPool layers for dimensionality reduction, and Transformer modules to capture high-order biological dependencies. Independently validated in each of 16 distinct The Cancer Genome Atlas cancer types, scBGDL significantly outperformed existing methods in prognostic accuracy (mean C-index: 0.7060 versus 0.6709 max competitor), demonstrating robustness and generalizability to diverse transcriptional architectures. To demonstrate clinical versatility, we further evaluated scBGDL in three therapeutic contexts using multicenter cohorts: lung adenocarcinoma survival prediction (n = 1099), epithelial ovarian cancer platinum-based chemotherapy response (n = 762), skin cutaneous melanoma immunotherapy outcome (n = 305). scBGDL consistently delivered robust risk stratification (log-rank P < 0.05 across cohorts), identified key driver edges, and uncovered clinically relevant biological interpretations. By enabling multimodal data integration and interpretable biological insights, scBGDL advances precision oncology for prognosis prediction, therapy optimization, and biomarker discovery. The source code for scBGDL model is available online (https://github.com/NEFLab/scBGDL).

Cytomorphology and immunocytochemical features of ovarian granulosa cell tumors in ascites or peritoneal washings: A retrospective review

AbstractAimTo summarize the cytomorphology and immunocytochemistry features of OGCT in ascites or peritoneal washings.MethodsAll cases of histology sections, cytology smears, cell block slides and immunohistochemical staining were reviewed. A panel of immunohistochemistry antibodies consisting of Inhibin, Calretinin, BerEP4 and MC was performed for diagnosis and differential diagnosis.ResultsSeven positive cases (21.2%) in ascites and peritoneal washings were identified in 33 patients with OGCT, which is higher than early studies with positive rate of 7.4%. Clinicopathologic features including tumor size and the incidence of endometrial atypical hyperplasia or carcinoma (EAH/EC) displayed no statistical difference between groups with positive and negative cytology. Immunocytochemical results usually showed typical staining pattern with α‐inhibin, calretinin positive and BerEP4, MC negative. Features of granulosa cells, including nuclear hyperplasia and overlapping, can be observed in all seven positive cases. Nuclear grooves or small conspicuous nucleoli were occasionally observed in the smear. However, features of cell clusters mimicking Call‐Exner bodies, cytoplasmic vacuoles or single cell necrosis were not found on smear. Call‐Exner bodies and mitosis can only be found on cell blocks. All cases of follow‐up information were available and three cases displayed progression and there was a statistical difference between groups with positive and negative cytology.ConclusionOGCT with positive cytology in ascites and peritoneal washings tend to have a larger tumor size and higher rates of disease progression. A panel of complementary biomarkers can greatly increase the detection rate and help in differential diagnosis in ascites or peritoneal washings of OGCT.

15Works
3Papers
2Collaborators
NeoplasmsPrognosis